Addition of Genetics to Quantitative MRI Facilitates Earlier Prediction of Dementia: A Non-invasive Alternative to Amyloid Measures

Schenker-Ahmed, Natalie M.; Bulsara, Nafisa; Yang, Lei; Huang, Lei; Iranmehr, Arya; Wu, Jian Nan; Graff, Alexander M; Dadakova, Tetiana; Chung, Hai Won; Tkach, Dmitry; Shomorony, Ilan; Shah, Naisha; Garst, Peter; Heister, R; Bureeva, Svetlana; Delport, Wayne; Karow, David S.; Brewer, James B.; Swisher, Christine Leon

doi:10.1101/731661

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the works in [52,53,31,54] examine the inter-relationships between CSF p-tau/Aβ42 ratio and several other biomarkers and their power in predicting change in cognitive ability. Even though Aβ-positivity has been identified as a strong predictor of disease status, little is known about the disease progression when only looking at a cohort including Aβ-positive subjects [32,55].…”

Section: Introductionmentioning

confidence: 99%

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Dansson

Stempfle

Egilsdóttir

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundIn Alzheimer’s disease (AD), amyloid- β (Aβ) peptides aggregate in the brain forming amyloid plaques, which are a key pathological hallmark of the disease. However, plaques may also be present in cognitively unimpaired elderly individuals. Therefore, it is of great value to explain the variance in disease progression among patients with Aβ pathology. MethodsA cohort of n= 2293 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database was selected to study heterogeneity in disease progression for individuals with Aβ plaque pathology. The analysis used baseline clinical variables including demographics, genetic markers and neuropsychological data to predict how the cognitive ability and AD diagnosis of subjects progressed using statistical models and machine learning. Due to the limited prevalence of Aβ pathology, models fit only to Aβ-positive subjects were compared to models fit to an extended cohort including subjects without established Aβ pathology, adjusting for covariate differences between the cohorts. ResultsAβ pathology status was determined based the Aβ 42 /Aβ 40 ratio. The best predictive model of change in cognitive test scores for Aβ-positive subjects at the two-year follow-up achieved an R 2 score of 0.388 while the best model predicting adverse changes in diagnosis achieved a weighted F1 score of 0.791. Conforming to expectations, Aβ-positive subjects declined faster on average than those without Aβ pathology, but the specific level of Aβ plaques was not predictive of progression rate. For the four-year prediction task of cognitive score change, the best model achieved an R 2 score of 0.325 and it was found that fitting models to the extended cohort substantially improved performance. Moreover, using all clinical variables outperformed the best model based only on baseline cognitive test scores which achieved an R 2 score of 0.228. ConclusionOur analysis shows that levels of Aβ plaques are not strong predictors of the rate of cognitive decline in Aβ-positive subjects. Baseline assessments of cognitive function accounts for the majority of variance explained in the prediction of two-year decline but is insufficient for achieving optimal results in longer-term predictions. Predicting changes both in cognitive test scores and in diagnosis provides multiple perspectives of the progression of potential AD subjects.

show abstract

Section: Introductionmentioning

confidence: 99%

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Dansson

Stempfle

Egilsdóttir

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

et al. 2021

View full text Add to dashboard Cite

Background In Alzheimer’s disease, amyloid- β (A β) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively unimpaired elderly individuals. Therefore, it is of great value to explain the variance in disease progression among patients with A β pathology. Methods A cohort of n=2293 participants, of whom n=749 were A β positive, was selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database to study heterogeneity in disease progression for individuals with A β pathology. The analysis used baseline clinical variables including demographics, genetic markers, and neuropsychological data to predict how the cognitive ability and AD diagnosis of subjects progressed using statistical models and machine learning. Due to the relatively low prevalence of A β pathology, models fit only to A β-positive subjects were compared to models fit to an extended cohort including subjects without established A β pathology, adjusting for covariate differences between the cohorts. Results A β pathology status was determined based on the A β42/A β40 ratio. The best predictive model of change in cognitive test scores for A β-positive subjects at the 2-year follow-up achieved an R2 score of 0.388 while the best model predicting adverse changes in diagnosis achieved a weighted F1 score of 0.791. A β-positive subjects declined faster on average than those without A β pathology, but the specific level of CSF A β was not predictive of progression rate. When predicting cognitive score change 4 years after baseline, the best model achieved an R2 score of 0.325 and it was found that fitting models to the extended cohort improved performance. Moreover, using all clinical variables outperformed the best model based only on a suite of cognitive test scores which achieved an R2 score of 0.228. Conclusion Our analysis shows that CSF levels of A β are not strong predictors of the rate of cognitive decline in A β-positive subjects when adjusting for other variables. Baseline assessments of cognitive function accounts for the majority of variance explained in the prediction of 2-year decline but is insufficient for achieving optimal results in longer-term predictions. Predicting changes both in cognitive test scores and in diagnosis provides multiple perspectives of the progression of potential AD subjects.

show abstract

Addition of Genetics to Quantitative MRI Facilitates Earlier Prediction of Dementia: A Non-invasive Alternative to Amyloid Measures

Cited by 2 publications

References 51 publications

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Contact Info

Product

Resources

About

Addition of Genetics to Quantitative MRI Facilitates Earlier Prediction of Dementia: A Non-invasive Alternative to Amyloid Measures

Cited by 2 publications

References 51 publications

Predicting Progression &amp; Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Predicting Progression &amp; Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Contact Info

Product

Resources

About

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's Disease